Ji et al., in their study entitled "Diosgenin, a Novel Aldose Reductase Inhibitor, Attenuates the Galactosemic Cataract in Rats," investigated the potentially protective role of diosgenin, an aldose reductase inhibitor (ARI), against the development of sugar cataract
Sugar cataract is the major ocular complication of diabetes, which seriously impairs the ocular function of diabetic subjects .
Although galactosemic cataract and diabetic cataract are together called "sugar cataract" , most researchers prefer to use galactose-induced cataract model to study the pathological mechanism of lens osmotic expansion [1, 9-11].
P-gp should be considered as a modulator in lens osmotic expansion of sugar cataract .
All the data were presented as mean [+ or -] standard deviation (SD); the grade of sugar cataract was analyzed by Mann-Whitney test, and other data were evaluated with one-way ANOVA (two-tailed test).
Diabetes is predicted to be about 552 million up to 2030 ; the majority of diabetic subjects are susceptible to develop sugar cataract over 10 years later.
In physiological condition, over 80% glucose enters the glycolysis pathway and almost no glucose enters the polyol pathway, the key cascade of sugar cataract [3, 5].
Here, we report a new-screened ARI, diosgenin, and its effects against sugar cataract in vitro and in vivo.
Formation of Sugar Cataract and the Ratio of Lens Weight to Body Weight.
Mechanism of cataracts caused by hyperglycemia or hypergalactosemia are similar, and they are together called "sugar cataract" [3, 17].
Briefly, this sugar cataract model was induced on 21-day male SD rats by only drinking galactose solution (12.5%-10%) in 15 days.
Cerami, "Nonenzymatic glycosylation, sulfhydryl oxidation, and aggregation of lens proteins in experimental sugar cataracts
," The Journal of Experimental Medicine, vol.